Cannabidiol Oral Solution – A New Class of Antiseizure Medication

Simona Lattanzi, Eugen Trinka, Pasquale Striano and Francesco Brigo

Cannabidiol (CBD) is a major component of the resin of the Cannabis sativa plant. CBD lacks psychoactive effects and has antiseizure properties. A plant-derived pharmaceutical formulation of purified CBD has been authorised for treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome. We review the pharmacology of CBD and the clinical studies investigating its efficacy and safety in these childhood epilepsies. CBD represents the first in a new class of antiseizure medications. CBD inhibits T-type calcium channels, modulates intracellular calcium ion levels and inhibits adenosine re-uptake. CBD has low oral bioavailability and high pharmacokinetic variability. It is a potent inhibitor of cytochrome P450 isoenzymes and the potential of drug–drug interactions exists. CBD is effective in reducing seizure frequency in patients with Lennox–Gastaut syndrome and Dravet syndrome. The most common adverse events are somnolence, decreased appetite, diarrhoea and increase of serum aminotransferases. Further studies are warranted to fully explore the potentialities of CBD in the treatment of epilepsy.

Keywords
Cannabidiol, epilepsy, Dravet syndrome, Lennox–Gastaut syndrome, antiseizure medications

Epilepsy is one of the most common neurological disorders, affecting around 70 million people worldwide. Its management is mainly symptomatic, and long-term seizure remission is achieved in most cases. One-third of patients, however, continue to experience seizures despite adequate treatment. Remarkably, the burden of refractory epilepsy has remained stable over the last decades despite increasing therapeutic resources, including third-generation antiseizure medications, neuro-modulation, surgical and dietary interventions.

Cannabidiol has been used to treat epilepsy since antiquity, and interest in cannabis-based therapies has recently increased. Cannabidiol (CBD) is a main component of the resin of the Cannabis sativa plant. CBD lacks psychoactive effects, carries no risk of abuse liability and has antiseizure properties. A plant-derived pharmaceutical formulation of purified CBD oral solution (Epidiolex®, Newbridge Biogen, Cambridge, UK) has been recently authorised by the US Food and Drug Administration as treatment, and by the European Medicines Agency (Epidiolex®, GW Pharma, Cambridge, UK) as adjunctive therapy, in conjunction with clobazam (CLB), for seizures associated with Dravet syndrome and Lennox–Gastaut syndrome in patients aged 2 years and older.

Here, we review the pharmacology of CBD and the clinical studies that have assessed its efficacy and safety in patients with Dravet syndrome or Lennox–Gastaut syndrome.

Clinical pharmacology
Pharmacodynamics
Compared with conventional antiseizure medications, CBD has a different mechanism of action. CBD is a 21-carbon terpenophenolic compound that results following decarboxylation from a cannabidiolic acid precursor (Figure 1). CBD has negligible activity at the cannabinoid receptors and its anti-convulsant effects acting on multiple molecular targets. CBD can elicit its effect mainly by the inhibition of T-type calcium channels and the modulation of intracellular calcium ion levels by inhibiting the G-protein coupled receptor 55 and activating the transient receptor potential cation channel subfamily V member 1 (TRPV1). CBD can negligibly act on the cannabinoid receptors and exerts its anti-convulsant effects acting on multiple molecular targets. CBD can elicit its effect mainly by the inhibition of T-type calcium channels and the modulation of intracellular calcium ion levels by inhibiting the G-protein coupled receptor 55 and activating the transient receptor potential cation channel subfamily V member 1 (TRPV1). CBD can also inhibit the re-uptake and influence the extracellular levels of adenosine, resulting in potential agonist activity at adenosine receptors. Antagonism of 5-HT1A adrenergic and μ-opioid receptors; inhibition of the uptake of dopamine, norepinephrine, 5-hydroxytryptamine and gamma-aminobutyric acid (GABAA); low-potency blockade of sodium channels; and inhibition of endocannabinoid metabolic enzymes and cyclo-oxygenase (COX) 1 and COX-2 are additional activities of CBD, but they are unlikely to represent principal anti-seizure mechanisms of action or occur at supra-pharmacological concentrations.

Support: No funding was received in the publication of this article.

Disclosures: Eugen Trinka has received speaker’s honoraria from UCB, Biogen, Genentech, Eisai, Teva, Newbridge, Sunovion Pharmaceuticals Inc., LivaNova and Novartis; consultancy fees from UCB, Biogen, Genentech, Eisai, Teva, Newbridge, GW Pharmaceuticals, Sunovion Pharmaceuticals Inc. and Novartis; and directorship fees from Neuroconsult Gmbh. Eugen Trinka’s institution has received grants from Biogen, Red Bull, Merck, UCB, European Union, FWF Österreichischer Fond zur Wissenschaftsförderung and Bundesministerium für Wissenschaft und Forschung. Pasquale Striano has received research support from Eisai, and unrestricted grants from Eisai, GW Pharmaceuticals and Sunovion Pharmaceuticals Inc. and a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors. The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Access: This article is freely accessible at touchNEUROLOGY® © Touch Medical Media 2020.

Received: 5 May 2020
Accepted: 1 July 2020
Published Online: 23 November 2020
Citation: European Neurological Review. 2020;15(1):19–26
Corresponding Author: Simona Lattanzi, Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60100 Ancona, Italy. E: alfierelattanzisimona@gmail.com

DOI: https://doi.org/10.17925/ENR.2020.15.1.19
Epilepsy

Pharmacokinetic properties

Following oral administration, CBD has low bioavailability and shows high intra- and inter-individual pharmacokinetic variability. Co-administration of CBD with a high-fat/high-calorie meal can increase maximum serum concentration (C\text{max}) five-fold, area under the curve (AUC) four-fold, and reduce the total variability compared with a fasted state in healthy volunteers. CBD diffuses into lipophilic tissues and has a high volume of distribution.\(^2\) It is highly bound to plasma protein and extensively metabolised in the liver and gut (primarily in the liver) by cytochrome P450 (CYP) isoenzymes, particularly CYP2C19 and CYP3A4, and uridine 5'-diphospho-glucuronosyltransferase (UGT) UGT1A7, UGT1A9 and UGT2B7 isomers.\(^2\) CBD is hydroxylated to the active metabolite 7-hydroxy-CBD (7-OH-CBD). A third metabolite, 6-hydroxy-CBD, is found at relatively low levels.\(^2\) The major route of excretion is intestinal, and 10–15% of the dose is eliminated in the urine. The main pharmacokinetic properties of CBD are shown in Table 1.

CBD can influence the activity of different enzymes involved in drug metabolism and is a potent CYP inhibitor, especially of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 (Table 2).\(^2\) There is a high potential of drug–drug interactions between CBD and both antiseizure and non-antiseizure medications due to the extensive hepatic metabolism and influence of CBD on enzymatic systems.

The best characterised pharmacokinetic drug–drug interaction is the bidirectional one between CBD and CLB. CBD can inhibit the CYP2C19 and raise the plasma levels of N-desmethylclobazam (N-CLB), the active metabolite of CLB. CLB leads to an approximately 50% increase in the exposure to 7-OH-CBD, by inhibiting CYP2D6 and glucuronidation.\(^2\) The increase in N-CLB exposure is not observed in patients concomitantly treated with stiripentol.\(^2\) Stiripentol is a strong CYP2C19 inhibitor and is expected to maximally elevate N-CLB levels. Nonetheless, it is not possible to completely rule out that a further benzodiazepine increase may occur in patients receiving lower than recommended (50 mg/kg/day) doses of stiripentol.\(^2\)

The concomitant administration of CBD and valproic acid is associated with an increased risk of transaminase elevations. The chemical structure of 7-COOH-CBD reveals similarities with the valproic acid metabolite associated with hepatotoxic properties, and the interaction observed \textit{in vitro} at the level of hepatic mitochondria could be the mechanism underlying the clinical findings.\(^2\)

Adjunctive treatment with CBD resulted in increased brivaracetam levels by 95–280% in a case series of five patients, but the clinical relevance of this effect is unknown; only two patients reported mild adverse events (AEs), leading to a reduction of brivaracetam in one patient.\(^2\) Concomitant administration of midazolam following repeated dosing of CBD has resulted in a relatively small reduction in the exposure to midazolam and a two-fold increase in the concentrations of 1'-hydroxymidazolam, the active metabolite.\(^2\) Linear increases in serum levels of eslicarbazepine, rufinamide, topiramate and zonisamide were observed with increasing CBD dose without any clinical correlates. There were no changes in drug levels of levetiracetam, clonazepam, vigabatrin and pregabalin with CBD dose titration.\(^2\) Although drug–drug interactions may potentially occur with ethosuximide, lacosamide, lamotrigine, perampanel, phenobarbital and phenytoin, no significant changes have been found with CBD dose titration.\(^2\)

**Table 1: Main pharmacokinetic properties of cannabidiol**

| Property | Details |
| --- | --- |
| Absorption | Low bioavailability (6–10%) |
| | Extensive first-pass metabolism in liver |
| | High intra- and inter-individual pharmacokinetic variability |
| | Absorption may be saturable |
| | Time to maximum plasma concentration (T\text{max}): 2.5–5.0 hours at steady state |
| | Steady state achieved within 2–4 days of twice-daily dosing |
| Distribution | High lipophilicity and high volume of distribution (V\text{d}/F: 32 L/kg) |
| | High protein binding (>94%) of CBD and its metabolites |
| | Low albumin levels/displacement interactions with other highly bound drugs (e.g. phenytoin, stiripentol, valproate) can affect free fraction |
| Metabolism | Plasma half-life: 56–61 hours after twice-daily dosing for 7 days |
| | Extensive metabolism by liver via CYP450 and UGT enzymes |
| | Phase 1 metabolism via CYP2C19 and CYP3A4 to 7-OH-CBD (active metabolite), 7-COOH-CBD and 6-OH-CBD (minor metabolite) |
| | Phase 2 conjugation via UGT1A7, UGT1A9, UGT2B7 |
| | Strong enzyme-inhibiting properties |
| | Dose adjustment required in patients with moderate or severe hepatic impairment |
| Excretion | Predominantly cleared by metabolism in liver and gut, and excreted in faeces |
| | Renal clearance of parent drug is minor pathway |
| | No interaction with major renal and hepatic transporters |
| | Dose adjustment not required for mild, moderate or severe renal impairment |

**Table 2: \textit{In vitro} effects of cannabidiol on enzymatic systems**

| Enzyme | Inhibition | Induction |
| --- | --- | --- |
| CYP1A2 | + | + |
| CYP2B6 | + | + |
| CYP2C8 | + | + |
| CYP2C9 | + | + |
| CYP2C19 | + | + |
| CYP2D6 | + | + |
| CYP3A4 | + | + |
| UGT1A9 | + | + |
| UGT2B7 | + | + |

CBD = cannabidiol; COOH-CBD = carboxy-CBD; CYP = cytochrome P450; OH-CBD = hydroxy-CBD; UGT = uridine 5'-diphospho-glucuronosyltransferase.
Cannabidiol Oral Solution – A New Class of Antiseizure Medication

Table 3: Summary of the main known interactions between cannabidiol and antiseizure medications

| Concomitant drug | Interaction | Mechanism |
|------------------|-------------|-----------|
| Brivaracetam     | • Increase in serum levels of brivaracetam | Inhibition of CYP2C19 |
| Clobazam         | • No effect on clobazam levels; increase in exposure to N-CLB | – |
| Clonazepam       | • No interaction | – |
| Eslicarbazepine  | • Linear increase in serum levels of eslicarbazepine with increasing CBD dose in adults | Inhibition of glucuronidation (by sesamis) |
| Levetiracetam    | • No interaction | – |
| Midazolam        | • Increase in 1'-hydroxymidazolam (active metabolite) levels | Inhibition of UGT2B7 |
| Pregabalin       | • No interaction | – |
| Rufinamide       | • Linear increase in serum levels of rufinamide with increasing CBD dose in children and adults | Inhibition of carboxy-esterases (by sesamis) |
| Stripentol       | • Increase in stripentol levels | Inhibition of CYP2C19 |
| Topiramate       | • Linear increase in serum levels of topiramate with increasing CBD dose in children and adults | Inhibition of CYP2C9/CYP2C19 |
| Valproate        | • No effect on serum concentrations of CBD and valproate | Possible mitochondrial toxicity |
| Vigabatrin       | • No interaction | – |
| Zonisamide       | • Linear increase in serum levels of zonisamide with increasing CBD dose in adults | Inhibition of CYP3A4 |

CBD = cannabidiol; N-CLB = N-desmethylclobazam; CYP = cytochrome P450; OH-CBD = hydroxy-CBD; UGT = uridine 5'-diphospho-glucuronosyltransferase.

A summary of the main known interactions between CBD and antiseizure medications is provided in Table 3.

Interactions between CBD and non-antiseizure drugs can be hypothesised based on metabolic pathways and actions on enzymatic systems. Although dedicated drug–drug interaction studies have not been conducted, the co-administration with moderate or strong inhibitors/inducers of CYP3A4 and CYP2C19 is expected to increase/reduce CBD plasma concentrations. Reduction/increase in CBD dosages should be considered based on tolerability and efficacy.

Clinical evidence of efficacy and safety

Randomised controlled trials

Five multicentre, randomised, double-blind, placebo-controlled trials evaluated the efficacy and/or safety of adjunctive CBD in patients with Dravet syndrome and Lennox–Gastaut syndrome. In all trials, CBD oral solution (100 mg/mL) was added to the antiseizure treatment. Characteristics of the trials and patients are summarised in Tables 4–6.

Antiseizure efficacy

In a greater reduction in convulsive and total seizure frequency (Table 7). Across the trials, the percentage of participants who presented a ≥50% decrease in convulsive seizure frequency was 45.4% with adjunctive CBD and 26.6% with placebo (risk ratio [RR] 1.69, 95% confidence interval [CI] 1.21–2.36; p=0.002). In the Lennox–Gastaut syndrome cohort, adjunctive CBD resulted in a significantly greater decrease in drop and total seizure frequency than placebo (Table 8). The overall percentage of participants who achieved ≥50% decrease in drop seizure frequency across all the trials was 40.0% with CBD and 19.3% with placebo (RR 2.12, 95% CI 1.48–3.03; p<0.001). Notably, CBD treatment improved the baseline status of patients with Dravet syndrome or Lennox–Gastaut syndrome as assessed by the Patient or Caregiver Global Impression of Change questionnaire.

One major issue in the clinical use of CBD is the concomitant administration of CLB, which is often a component of the regimen used to treat Dravet syndrome and Lennox–Gastaut syndrome. Increased systemic levels of N-CLB and 7-OH-CBD might enhance the pharmacological effects. CBD is also a positive allosteric modulator of GABA A receptors and a pharmacodynamic interaction occurs, where co-administration of CBD further enhances GABA A-mediated inhibitory activity. Significant drug–drug interactions between CBD and CLB have overall raised doubts about the intrinsic antiseizure activity of CBD and imposed prescription limits in Europe. In this regard, a recent systematic review and meta-analysis showed that adjunctive CBD was associated with a higher rate of seizure response in comparison to placebo at the dosage of both 10 and 20 mg per kg/day in patients with Dravet syndrome or Lennox–Gastaut syndrome, irrespective of the concomitant use of CLB.

Safety and tolerability

During pivotal studies, drug discontinuation and AEs were more common in the CBD than placebo groups, mostly at the highest dose. Most AEs were mild or moderate, and usually resolved with treatment. The most frequent AEs associated with CBD were somnolence, decreased appetite and diarrhoea (Table 9). Somnolence was more common among participants who were also taking CLB and a decrease in the dose of the benzodiazepine was more frequently observed among patients treated with CBD than placebo. Drug–drug interactions leading to an increased serum-level of CLB and its metabolites are likely to contribute to the development of somnolence or sedation. As it is clinically difficult to distinguish benzodiazepine toxicity from CBD-related AEs, therapeutic drug monitoring is recommended before the administration of CBD and after any dosage increase.

CBD has been associated with raised liver enzymes, which was documented to be the most common severe AE and explained half of the treatment withdrawals in the pivotal studies. Transaminase elevations generally appear during the first 1–3 months of treatment, and rare
cases have been known to develop up to 200 days after treatment.\textsuperscript{47} Resolution of transaminase elevations usually occurs after CBD is tapered or discontinued, or the dose of a concomitant antiseizure medication is reduced; in about one-third of the cases, transaminase elevations have resolved spontaneously during continued treatment with CBD, without dose reduction.\textsuperscript{47}

Risk factors for transaminase elevation include concomitant use of valproic acid and CLB, CBD dose, and baseline transaminase levels. Most cases of aminotransferases elevations developed in participants taking concomitant valproic acid, and some resolved during CBD treatment after the reduction in valproic acid dosage.\textsuperscript{48} Concomitant use of CLB also increases the risk of transaminase elevations, albeit to a lesser extent. Transaminase elevations greater than three times the upper normal limit occurred in 30% of the participants taking both concomitant valproic acid and CLB, about 20% of the participants under concomitant treatment with valproic acid (without CLB), 4% of the participants concomitantly administered with CLB (without valproic acid), and 3% of the participants treated neither with valproic acid nor CLB. Transaminase elevations are dose-related: they have been known to occur in 15–20% of participants treated with CBD at the daily dose of 20 mg/kg and 1% of participants treated with CBD at the daily dosage of 10 mg/kg.\textsuperscript{49} Patients with levels of liver enzymes above normal limits before starting treatment have also been found to have higher rates of further elevations: the incidence of

Table 4: Characteristics of the randomised controlled trials

| Trial               | Design                                                                 | Inclusion criteria                                                                 |
|---------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| GWPCARE1 Part A\textsuperscript{30} | Phase III, multicentre (US and UK), parallel-group, randomised, placebo-controlled trial:  
  • 4-week observational baseline  
  • 3-week double-blind treatment period (starting at 2.5 mg/kg/day and increasing by 2.5–5.0 mg/kg every other day to randomised dose)  
  • ≤10 days tapering-off  
  • 4-week safety follow-up  
  • Treatment arms: oral placebo and oral CBD (5, 10, 20 mg/kg) | • Aged 4–10 years  
• Documented history of DS not completely controlled by current ASM  
• Fewer than four convulsive seizures during the 4-week baseline period  
• Current treatment with one or more ASMs at a stable dose for at least 4 weeks before screening |
| GWPCARE1 Part B\textsuperscript{35} | Phase III, multicentre (US and EU), parallel-group, randomised, placebo-controlled trial:  
  • 4-week observational baseline  
  • 14-week double-blind treatment period (2-week titration, 12-week stable dosing maintenance)  
  • ≤10 days tapering-off  
  • 4-week safety follow-up  
  • Treatment arms: oral placebo and oral CBD (20 mg/kg) | • Aged 2–18 years  
• Documented history of DS not completely controlled by current ASM  
• At least four convulsive seizures during the 4-week baseline period  
• Current treatment with one or more ASMs at a stable dose for at least 4 weeks before screening |
| GWPCARE2\textsuperscript{36} | Phase III, multicentre (US, EU, Australia, Israel), parallel-group, randomised, placebo-controlled trial:  
  • 4-week observational baseline  
  • 14-week double-blind treatment period (2-week titration, 12-week stable dosing maintenance)  
  • ≤10 days tapering-off  
  • 4-week safety follow-up  
  • Treatment arms: oral placebo and oral CBD (10, 20 mg/kg) | • Aged 2–18 years  
• Documented history of DS not completely controlled by current ASM  
• At least four convulsive seizures during the 4-week baseline period  
• Current treatment with one or more ASMs at a stable dose for at least 4 weeks before screening |
| GWPCARE3\textsuperscript{37} | Phase III, multicentre (US, UK, Spain, France), parallel-group, randomised, placebo-controlled trial:  
  • 4-week observational baseline  
  • 14-week double-blind treatment period (2-week titration, 12-week stable dosing maintenance)  
  • ≤10 days tapering-off  
  • 4-week safety follow-up  
  • Treatment arms: oral placebo and oral CBD (10, 20 mg/kg) | • Aged 2–55 years  
• Clinical diagnosis of LGS (including documented slow [<3.0 Hz] spike-and-wave electroencephalographic pattern) and evidence of at least two types of generalised seizures, including drop seizures, for at least 6 months  
• At least two drop seizures each week during the 4-week baseline period  
• Current treatment with one or more ASMs at a stable dose for at least 4 weeks before screening  
• Documented failures on at least two ASMs |
| GWPCARE4\textsuperscript{38} | Phase III, multicentre (US, Netherlands, Poland), parallel-group, randomised, placebo-controlled trial:  
  • 4-week observational baseline  
  • 14-week double-blind treatment period (2-week titration, 12-week stable dosing maintenance)  
  • ≤10 days tapering-off  
  • 4-week safety follow-up  
  • Treatment arms: oral placebo and oral CBD (20 mg/kg) | • Aged 2–55 years  
• Clinical diagnosis of LGS (including documented slow [<3.0 Hz] spike-and-wave electroencephalographic pattern) and evidence of at least two types of generalised seizures, including drop seizures, for at least 6 months  
• At least two drop seizures each week during the 4-week baseline period  
• Current treatment with one or more ASMs at a stable dose for at least 4 weeks before screening  
• Documented failures on at least two ASMs |

ASM = antiseizure medication; CBD = cannabidiol; DS = Dravet syndrome; LGS = Lennox–Gastaut syndrome.
Open-label studies

Patients with Dravet syndrome or Lennox–Gastaut syndrome who completed the randomised controlled trials were invited to enrol in a long-term, open-label extension trial (GWPCARE5; ClinicalTrials.gov identifier, NCT02224573). Based on response and tolerance, CBD could be reduced or increased up to 30 mg/kg/day. Clinically meaningful reductions in seizure frequency were maintained on long-term treatment up to 48 weeks according to pre-specified interim analyses, and safety profile was similar to the one observed in pivotal trials.49,50

Expanded access programme results provide further supporting evidence regarding the long-term effectiveness of add-on CBD in subjects diagnosed with Dravet syndrome or Lennox–Gastaut syndrome.51 Over a median treatment duration of 78.3 weeks (range 4.1–146.4 weeks), treatment withdrawal occurred in 28% of the patients, primarily due to lack of efficacy. Between weeks 12 and 96, median daily CBD dose ranged from 21–25 mg/kg. At 12 weeks, add-on CBD reduced median monthly major motor seizures by 50% and total seizures by 44%, with consistent reductions through 96 weeks. The proportions of patients with ≥50% and 100% reductions in major motor seizures were 53% and 6% at 12 weeks, and the proportions with corresponding reductions in total seizures were 46% and 5%. The safety profile was acceptable, and somnolence and diarrhoea were the most frequent AEs.51

Different studies have evaluated changes in seizure frequency and occurrence of AEs associated with highly purified CBD as an add-on treatment in patients with treatment-resistant epilepsy.52–60 Marked heterogeneity was seen in treatment duration and drug daily doses, ranging up to 50 mg/kg, and the prevalence of patients with Dravet syndrome or Lennox–Gastaut syndrome was not always provided.

### Table 5: Demographics and baseline characteristics of patients with Dravet syndrome

| Trial    | GWPCARE1 Part A52 | GWPCARE1 Part B53 | GWPCARE254 |
|----------|-------------------|-------------------|-------------|
| Treatment arm | CBD 5 mg/kg (n=10) | CBD 10 mg/kg (n=8) | CBD 20 mg/kg (n=9) | Placebo (n=7) | CBD 20 mg/kg (n=61) | Placebo (n=59) | CBD 10 mg/kg (n=66) | CBD 20 mg/kg (n=67) | Placebo (n=65) |
| Characteristic | | | | | | | | | |
| Male sex, % | 50.0 | 37.5 | 33.3 | 71.4 | 57.4 | 45.8 | 40.9 | 53.7 | 47.7 |
| Mean age, years (SD) | 7.2 (1.9) | 7.4 (2.1) | 8.7 (1.8) | 7.0 (0.9) | 9.7 (4.7) | 9.8 (4.8) | 9.2 (3.3) | 9.3 (4.3) | 9.6 (4.6) |
| Caucasian, % | 90.0 | 50.0 | 88.9 | 42.9 | 72.1 | 84.7 | 86.0 | 96.0 | 85.0 |
| Median number of prior ASMs (range) | 3 (0–11) | 3.5 (0–5) | 4 (2–8) | 5 (1–5) | 4 (0–26) | 4 (0–14) | 4 (0–19) | 4 (0–11) |
| Median number of concomitant ASMs (range) | 3 (1–4) | 3 (2–3) | 3 (1–4) | 2 (1–3) | 3 (1–5) | 3 (1–5) | 3 (1–5) | 3 (1–4) |

**ASM = antiseizure medication; CBD = cannabidiol; SD = standard deviation.**

### Table 6: Demographics and baseline characteristics of patients with Lennox–Gastaut syndrome

| Trial    | GWPCARE357 | GWPCARE458 |
|----------|-------------|-------------|
| Treatment arm | CBD 10 mg/kg (n=73) | CBD 20 mg/kg (n=76) | Placebo (n=76) | CBD 20 mg/kg (n=86) | Placebo (n=85) |
| Characteristic | | | | | |
| Male sex, % | 55 | 59 | 58 | 52 | 51 |
| Mean age, years (SD) | 15.4 (9.9) | 16.0 (10.8) | 15.3 (9.3) | 15.5 (8.7) | 15.3 (9.8) |
| Caucasian, % | 84.9 | 88.2 | 90.8 | 87.0 | 93.0 |
| Median number of prior ASMs (range) | 6 (0–21) | 6 (1–18) | 6 (1–22) | 6 (1–18) | 6 (0–28) |
| Median number of concomitant ASMs (range) | 3 (1–5) | 3 (0–5) | 3 (1–5) | 3 (1–5) | 3 (1–4) |

**ASM = antiseizure medication; CBD = cannabidiol; SD = standard deviation.**

---

**European Neurological Review**

Cannabidiol Oral Solution – A New Class of Antiseizure Medication

---

**Table 5: Demographics and baseline characteristics of patients with Dravet syndrome**

| Characteristic | GWPCARE1 Part A52 | GWPCARE1 Part B53 | GWPCARE254 |
|---------------|-------------------|-------------------|-------------|
| Male sex, %   | 50.0              | 37.5              | 33.3        |
| Mean age, years (SD) | 7.2 (1.9)         | 7.4 (2.1)         | 8.7 (1.8)   |
| Caucasian, %  | 90.0              | 50.0              | 88.9        |
| Median number of prior ASMs (range) | 3 (0–11)          | 3.5 (0–5)        | 4 (2–8)     |
| Median number of concomitant ASMs (range) | 3 (1–4)           | 3 (2–3)          | 3 (1–4)     |

**ASM = antiseizure medication; CBD = cannabidiol; SD = standard deviation.**

---

**Table 6: Demographics and baseline characteristics of patients with Lennox–Gastaut syndrome**

| Characteristic | GWPCARE357 | GWPCARE458 |
|---------------|-------------|-------------|
| Male sex, %   | 55          | 59          | 58          | 52          | 51          |
| Mean age, years (SD) | 15.4 (9.9)  | 16.0 (10.8) | 15.3 (9.3)  | 15.5 (8.7)  | 15.3 (9.8)  |
| Caucasian, %  | 84.9        | 88.2        | 90.8        | 87.0        | 93.0        |
| Median number of prior ASMs (range) | 6 (0–21)   | 6 (1–18)    | 6 (1–22)    | 6 (1–18)    | 6 (0–28)    |
| Median number of concomitant ASMs (range) | 3 (1–5)    | 3 (0–5)     | 3 (1–5)     | 3 (1–5)     | 3 (1–4)     |

**ASM = antiseizure medication; CBD = cannabidiol; SD = standard deviation.**

---

**Cannabidiol Oral Solution – A New Class of Antiseizure Medication**
Overall, CBD improved seizure control and was effective in reducing seizure frequency with or without concomitant CLB. The most common AEs observed across the cohorts included somnolence, decreased appetite and gastrointestinal symptoms; no major safety concerns emerged. Beneficial effects on sleep, behaviour, motor skills, social interactions, mood and quality of life were observed and were independent of treatment response. Long-term administration of pharmaceutical-grade CBD was cognitively well-tolerated; modulation of the activity and functional connectivity related to attentional control processes was also suggested to improve cognitive performance.

**Dosage, administration and use in specific populations**

CBD is administered at the starting dosage of 2.5 mg/kg (twice daily; daily dosage of 5 mg/kg). After 1 week, the dose can be increased to a maintenance dose of 5 mg/kg (twice daily). Patients who tolerate CBD at 10 mg/kg/day and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance dosage of 10 mg/kg twice daily, in weekly increments of 2.5 mg/kg twice daily, as tolerated.

Randomised controlled studies of CBD in the treatment of Dravet syndrome and Lennox–Gastaut syndrome did not enrol participants with aged <2 years or >55 years. According to a general rule, dose selection in elderly patients should be cautious, usually starting at the low end of the dosing range, considering the greater frequency of decreased hepatic, renal, or cardiac function, comorbidities and concomitant drug therapies.

---

**Table 7: Efficacy of adjunctive cannabidiol in patients with Dravet syndrome**

| Trial | GWPCARE1 Part B<sup>35</sup> | GWPCARE3<sup>36</sup> |
|-------|-----------------------------|------------------------|
| CBD 20 mg/kg | Placebo | CBD 10 mg/kg | CBD 20 mg/kg | Placebo |
| **Endpoint** | | | | |
| **Primary analysis: percentage change in convulsive seizure frequency** | | | | |
| Median (IQR) | 38.9 (4.8–69.5) | 31.1 (20.2–52.5) | 37.9 (3.7–57.6)* | 45.7 (34.2–55.2)* | 29.6 (11.9–39.4)* |
| Estimated median difference: CBD versus placebo (95% CI) | 22.8 (5.4–41.1) (p=0.012) | 0.7 (0.5–0.9)† (p=0.001) | 0.7 (0.6–1.0)† (p=0.003) | | |
| **Secondary analysis: ≥50% reduction in convulsive seizure frequency** | | | | |
| Number of patients (%) | 26 (42.6) | 16 (27.1) | 29 (43.9) | 33 (49.3) | 17 (26.2) |
| Odds ratio: CBD versus placebo (95% CI) | 2.00 (0.93–4.30) (p=0.078) | 2.21 (1.06–4.62) (p=0.033) | 2.74 (1.32–5.70) (p=0.007) | | |
| Estimated median difference: CBD versus placebo (95% CI) | 19.2 (1.1–39.25) (p=0.013) | 0.6 (0.5–0.8)† (p=0.001) | 0.7 (0.6–1.0)† (p=0.002) | | |

<sup>*</sup>Least squares mean (95% CI). <sup>†</sup>Estimated treatment ratio from negative binominal regression analysis. CBD = cannabidiol; CI = confidence interval; IQR = interquartile range.

**Table 8: Efficacy of adjunctive cannabidiol in patients with Lennox–Gastaut syndrome**

| Trial | GWPCARE3<sup>37</sup> | GWPCARE4<sup>38</sup> |
|-------|-----------------------------|------------------------|
| CBD 10 mg/kg | CBD 20 mg/kg | Placebo | CBD 20 mg/kg | Placebo |
| **Endpoint** | | | | |
| **Primary analysis: percentage change in drop seizure frequency** | | | | |
| Median (IQR) | 37.2 (5.6–63.8) | 41.9 (1.3–72.4) | 17.2 (0.9–37.1) | 43.9 (1.9–69.6) | 21.8 (-1.7–45.7) |
| Estimated median difference: CBD versus placebo (95% CI) | 19.2 (7.7–31.2) (p=0.002) | 21.6 (6.7–34.8) (p=0.003) | – | 17.2 (4.1–30.3) (p=0.014) | |
| **Secondary analysis: ≥50% reduction in drop seizure frequency** | | | | |
| Number of patients (%) | 26 (35.6) | 30 (39.5) | 11 (14.5) | 38 (44.2) | 20 (23.5) |
| Odds ratio: CBD versus placebo (95% CI) | 3.3 (1.5–7.3) (p=0.003) | 3.9 (1.8–8.5) (p=0.001) | – | 2.6 (1.3–5.0) (p=0.004) | |
| Estimated median difference: CBD versus placebo (95% CI) | 19.5 (7.5–30.4) (p=0.002) | 18.8 (4.4–31.8) (p=0.009) | – | 21.1 (9.4–33.3) (p=0.001) | |

CBD = cannabidiol; CI = confidence interval; IQR = interquartile range.
In patients with moderate or severe hepatic impairment, CBD dose adjustment is recommended due to the increase in exposure and slower titration may be necessary; no adjustment is required in patients with mild hepatic impairment (Table 10). The labelling for CBD oral solution currently does not list any black box warnings. CBD is contraindicated in patients with a history of hypersensitivity to CBD or any other ingredients in CBD oral solution.

### Conclusion

The authorisation of CBD for the treatment of two forms of childhood epilepsy is a turning point in the use of cannabinoids to manage epileptic conditions. CBD oral solution (Epidiolex) is the only pharmacological substance deriving from the cannabis plant that has undergone review through the approval processes and represents the first in a new class of antiseizure medication. Remarkably, results cannot be extrapolated to other cannabis-derived products and non-purified forms of medical marijuana or its components. Indeed, the evidence about the efficacy and safety of cannabis-based products or synthetic cannabinoids for medicinal use like CBD-enriched cannabis oil containing CBD plus tetrahydrocannabinol (THC), TIL-TC150, and dronabinol, and non-medicinal CBD or CBD products is mainly limited to uncontrolled studies, small series, case reports and surveys, and does not allow one to draw firm conclusions. In many cases, unspecified products with unknown composition and dosage, including oral cannabis extracts and artisanal or hemp-based CBD preparations, were used. In particular, non-medicinal CBD products are widely sold as herbal remedies but are not scheduled and regulated as medicinal products. They are widely available on the internet and from health food retailers, but they lack quality standards; they contain CBD and THC in varying quantities and proportions, often at concentrations widely different from those reported in their labels, and the amount of CBD is typically far lower than in clinical trials. The use of such products can be also associated with the occurrence of AEs and intoxication from psychotropic constituents, including seizure exacerbation.

Recently, CBD has also been demonstrated to significantly reduce seizures associated with tuberous sclerosis complex, and research is ongoing to evaluate this drug in infantile spasms. Additional research in different types of epilepsy, including refractory focal epilepsy, is needed to further explore and understand the potentialities of CBD.

### Table 9: Adverse events of adjunctive cannabidiol versus placebo

| Adverse event            | Number of events/number of participants | Cannabidiol | Placebo |
|--------------------------|----------------------------------------|-------------|---------|
| Any adverse event        | 402/456                                | 222/292     |         |
| Any severe adverse event | 90/456                                 | 26/292      |         |
| Somnolence                | 110/456                                | 28/292      |         |
| Decreased appetite        | 96/456                                 | 22/292      |         |
| Diarrhoea                 | 83/456                                 | 28/292      |         |
| Pyrexia                   | 72/456                                 | 35/292      |         |
| Vomiting                  | 50/456                                 | 30/292      |         |
| Fatigue                   | 51/456                                 | 15/292      |         |
| Upper respiratory infection| 39/456                                | 25/292      |         |
| Increased aminotransferases* | 68/456                    | 2/292       |         |

*Increase of serum alanine or aspartate aminotransferases concentrations by three-fold or greater the upper limit of the normal range.

### Table 10: Dose adjustments for cannabidiol in patients with hepatic impairment

| Dose                          | Starting | Maintenance | Maximum recommended |
|-------------------------------|---------|------------|---------------------|
| Mild (Child–Pugh A)           | 2.5 mg/kg BID (5 mg/kg/day) | 5 mg/kg BID (10 mg/kg/day) | 10 mg/kg BID (20 mg/kg/day) |
| Moderate (Child–Pugh B)       | 1.25 mg/kg BID (2.5 mg/kg/day) | 2.5 mg/kg BID (5 mg/kg/day) | 5 mg/kg BID (10 mg/kg/day) |
| Severe (Child–Pugh C)         | 0.5 mg/kg BID (1 mg/kg/day) | 1 mg/kg BID (2 mg/kg/day) | 2 mg/kg BID (4 mg/kg/day) |

BID = bid in (twice daily).
Lennox–Gastaut syndrome (GWPCARE6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–96.

Lattanzi S, Brigo F, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a patient-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–9.

Leahy J, Chu-Shore C, Fisher B. Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome. Neuruphyschiatr Dis Treat. 2011;7:673–81.

Anderson JL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60:2224–34.

Rogawski MA. Reduced efficacy and risk of seizure aggravation when cannabidiol is used without clobazam. Epilepsy Behav. 2020;103:155056.

Lattanzi S, Trinka E, Isla J, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61:1090–8.

US Food and Drug Administration. FDA briefing document: public commentary regarding clobazam. 2015. Available at: www.accessdata.fda.gov/drugsatfda_docs/meeting/2015/210365lbl.pdf (accessed 8 July 2020).

Epidiolex (cannabidiol) oral solution – highlights of prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf (accessed 8 July 2020).

Crippa JA, Crippa AC, Hallak JE, et al. Δ9-THC intoxication by smoking: evidence for both tolerance and increased subjective experiences. J Neuropsychopharmacol. 2009;34:1552–62.

Vandrey R, Raber JC, Raber ME, et al. Cannabidiol dose and cannabinoid dose and cannabinoid receptor subtypes: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;99:741–53.

O’Connell BK, Glass D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70:341–8.

Vanroey N, Raber JC, Raber ME, et al. Cannabidiol and label accuracy in edible medical cannabis products. JAMA. 2015;313:2491–3.

Crippa JA, Crippa AC, Hallak JE, et al. 5–9-THC intoxication by smoking: evidence for both tolerance and increased subjective experiences. J Neuropsychopharmacol. 2009;34:1552–62.

Cloyd JC, Lackner TE, Leppik EI. Antiepileptics in the elderly. Drugs Today (Barc). 1994;30:389–99.

Zaccara G, Lattanzi S. Cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60:2224–34.

Rogawski MA. Reduced efficacy and risk of seizure aggravation when cannabidiol is used without clobazam. Epilepsy Behav. 2020;103:155056.

Lattanzi S, Trinka E, Isla J, et al. Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia. 2020;61:1090–8.

US Food and Drug Administration. FDA briefing document: public commentary regarding clobazam. 2015. Available at: www.accessdata.fda.gov/drugsatfda_docs/meeting/2015/210365lbl.pdf (accessed 8 July 2020).

Epidiolex (cannabidiol) oral solution – highlights of prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf (accessed 8 July 2020).

Crippa JA, Crippa AC, Hallak JE, et al. Δ9-THC intoxication by smoking: evidence for both tolerance and increased subjective experiences. J Neuropsychopharmacol. 2009;34:1552–62.